New Treatment Halts Progress of Alzheimer's Disease

view article

Published at: www.abdn.ac.uk

Critical thinking and creativity in AD research

November 9, 2009

Analysis by: GLG Expert Contributor

The recetn  clinical results suggest that plaque removal is not enough to halt progressive neurodegeneration in Alzheimer Disease and prompt some intriguing challenges to the amyloid hypothesis.

Concerns about the Rember Phase 2 data

August 6, 2008

Analysis by: GLG Expert Contributor

While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.

William ShannonFounder and PresidentBioRankings, LLC

Biostatistical and Experimental Design Assessment of Research on Tau Tangle Targeting for Alzheimer’s Disease

August 5, 2008

Slowing the progression of Alzheimer's disease by attacking tau tangles is a novel idea that should be considered a viable treatment alternative, especially in light of the failings of some recent beta-amyloid treatment strategies (e.g., Flurizan).   At the 2008 International Conference on Alzheimer's Disease (ICAD 2008), Dr. Claude Wischik (Univ. of Aberdeen and TauRx Pharmaceuticals) and colleagues gave positive research reports on treatments developed to target and dissolve the tau tangle protein complex, including the first report of an international randomized Phase II clinical trial of Rember™.   We performed a comprehensive biostatistical and experimental design assessment of the pre-clinical and clinical research reported by Dr. Wischik and colleagues at ICAD 2008, to see if the evidence for tau tangle targeting has early scientific validity.